In those cases where p53 is absent or mutant and thus unable to activate its target genes, the administration of Nutlin or similar Mdm2 inhibitors will not interfere with the efficacy of Wee1 inhibitors against tumor cells, as exemplified by p53−/− HCT116 cells in this study (Fig. 3B). Here, MDM2 is linked to neoplasm.